Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 196, Issue 1, Pages 105-109Publisher
WILEY
DOI: 10.1111/bjh.17772
Keywords
multiple myeloma; thrombosis; anticoagulation; myeloma therapy; haematological oncology
Categories
Ask authors/readers for more resources
The incidence of venous thromboembolism varies across different regimens in newly diagnosed multiple myeloma patients, with higher rates seen in those treated with KRD induction. The use of low-dose rivaroxaban thromboprophylaxis can mitigate this risk without an observable increase in bleeding rates.
Incidence of venous thromboembolism (VTE) varies across different regimens in newly diagnosed multiple myeloma (NDMM) patients. Limited data exist on the use of direct oral anticoagulants as thromboprophylaxis in the setting of haematologic malignancies, specifically multiple myeloma. In this retrospective study of 305 NDMM patients, VTE rates in those treated with carfilzomib, lenalidomide, dexamethasone (KRD) + aspirin (ASA), bortezomib, lenalidomide, dexamethasone (RVD) + ASA, and KRD + rivaroxaban were statistically significant, 16 center dot 1%, 4 center dot 8%, and 4 center dot 8%, respectively. The findings confirm a higher incidence of VTE when using KRD induction compared to RVD induction and reveal that the use of low-dose rivaroxaban thromboprophylaxis can mitigate this risk without an observable increase in bleeding rates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available